KLRS – kalaris therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

KLRS

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

4/16

05:03 am

klrs

Kalaris Therapeutics (KLRS) is now covered by Morgan Stanley. They set an "overweight" rating on the stock.

High Report

Kalaris Therapeutics (KLRS) is now covered by Morgan Stanley. They set an "overweight" rating on the stock.

Report

3/17

08:00 am

klrs

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Medium Report

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Report

3/15

01:05 am

klrs

Kalaris Therapeutics (KLRS) was upgraded by Wall Street Zen from "sel

Low Report

Kalaris Therapeutics (KLRS) was upgraded by Wall Street Zen from "sel

Report

2/21

02:04 am

klrs

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at Wall Stre

Medium Report

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at Wall Stre

Report

1/31

01:33 am

klrs

Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by analysts at Wall St

Low Report

Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by analysts at Wall St

Report

1/28

04:05 pm

klrs

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

Low Report

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.